Insider Shareholders with Direct Ownership of Aclaris Therapeutics, Inc. (ACRS)
This section provides a comprehensive overview of the insiders with direct ownership of Aclaris Therapeutics, Inc. (ACRS). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Aclaris Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Neal Walker
INTERIM CEO |
758,464 | 470,985 | 1,433,630 $4.19 Million | 50 |
Dec 04, 2024
Reduced 4.55%
|
| 693,821 | 0 | 710,030 $2.07 Million | 5 |
Nov 19, 2024
Added 48.43%
|
|
|
Frank Ruffo
Chief Financial Officer |
118,633 | 128,442 | 201,883 $589,498 | 18 |
Mar 10, 2022
Reduced 5.97%
|
|
Joseph Monahan
Chief Scientific Officer |
297,733 | 183,082 | 171,783 $501,606 | 27 |
Dec 10, 2024
Reduced 8.03%
|
|
Kamil Ali Jackson
Chief Legal Officer |
173,544 | 136,183 | 160,214 $467,824 | 24 |
Jan 03, 2022
Added 4.24%
|
|
David N. Gordon
Chief Medical Officer |
122,397 | 62,485 | 147,447 $430,545 | 9 |
Jul 13, 2021
Reduced 1.75%
|
| 29,272 | 0 | 53,163 $155,235 | 5 |
Jun 01, 2024
Added 8.06%
|
|
|
Douglas J. Manion
Pres and CEO |
55,375 | 13,562 | 41,813 $122,093 | 6 |
Jan 01, 2024
Reduced 17.91%
|
|
James Loerop
Chief Business Officer |
44,705 | 10,688 | 34,017 $99,329 | 5 |
Feb 01, 2024
Reduced 7.02%
|
| 27,023 | 10,209 | 33,523 $97,887 | 8 |
Jun 01, 2024
Added 12.2%
|
|
| 12,523 | 0 | 28,732 $83,897 | 3 |
Jun 01, 2024
Added 13.96%
|
|
| 12,523 | 0 | 28,732 $83,897 | 3 |
Jun 01, 2024
Added 13.96%
|
|
|
Kevin Balthaser
Chief Financial Officer |
30,415 | 6,418 | 24,697 $72,115 | 15 |
Sep 01, 2024
Reduced 1.14%
|
| 12,523 | 0 | 16,961 $49,526 | 3 |
Jun 01, 2024
Added 21.55%
|
|
| 12,523 | 0 | 12,523 $36,567 | 3 |
Jun 01, 2024
Added 27.12%
|
|
|
Gail Cawkwell
Chief Medical Officer |
15,000 | 5,407 | 9,593 $28,011 | 2 |
Jul 01, 2023
Reduced 36.05%
|
| 12,523 | 19,565 | 9,167 $26,767 | 4 |
Jun 01, 2024
Added 33.7%
|